Piper Jaffray analyst Joshua Schimmer says today's pullback in shares of bluebird bio (BLUE) creates "another buy-in opportunity." The news sending the stock lower related to a beta thalassemia patient who received the company's first generation HPV569 lenti vector. After "an impressive" sever-year period of transfusion independence, the patient recently received two blood transfusions due to anemia, Schimmer tells investors in a research note. The selloff is an overreaction as bluebird's Lentiglobin represents a "much better technology with significantly higher transduction efficiency" than the earlier generation constructs, the analyst contends. Further, he believes the patient may have had marrow burn-out or other confounding causes of anemia. Schimmer reiterates an Overweight rating on bluebird with a $213 price target. The stock closed down $3.74 to $81.83 after touching an intraday low of $70.57. Other names that moved lower following bluebird's intraday news release include uniQure (QURE), Juno Therapeutics (JUNO) and Five Prime (FPRX).